Forest Laboratories (FRA:FQX) 5-Year Yield-on-Cost % : 0.00 (As of May. 28, 2024)

View and export this data going back to . Start your Free Trial

What is Forest Laboratories 5-Year Yield-on-Cost %?

Forest Laboratories's yield on cost for the quarter that ended in Mar. 2014 was 0.00.

The historical rank and industry rank for Forest Laboratories's 5-Year Yield-on-Cost % or its related term are showing as below:

FRA:FQX's 5-Year Yield-on-Cost % is not ranked ^*
in the Drug Manufacturers industry.
Industry Median: 2.13
* Ranked among companies with meaningful 5-Year Yield-on-Cost % only.

Competitive Comparison of Forest Laboratories's 5-Year Yield-on-Cost %

For the Drug Manufacturers - Specialty & Generic subindustry, Forest Laboratories's 5-Year Yield-on-Cost %, along with its competitors' market caps and 5-Year Yield-on-Cost % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Forest Laboratories's 5-Year Yield-on-Cost % Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Forest Laboratories's 5-Year Yield-on-Cost % distribution charts can be found below:

* The bar in red indicates where Forest Laboratories's 5-Year Yield-on-Cost % falls into.

Forest Laboratories 5-Year Yield-on-Cost % Calculation

Dividend Yield % and dividend growth of a stock is an important factor for income investors. But if company A raises its dividend constantly faster than company B, company A's future dividend yield might be much higher than Company B's even if their yields are the same now and their stock prices do not change.

Yield on Cost assumes that you buy and the stock today, and hold it for 5 years. If the company raises it dividends at the same rate as it did over the past 5 years, the dividends investors receive annually in 5 years relative to the stock price today.

Therefore, Yield-on-Cost of Forest Laboratories is calculated as

Yield-on-Cost

Dividend Yield %

Dividend Growth Rate)^5

Forest Laboratories (FRA:FQX) 5-Year Yield-on-Cost % Explanation

Of course the risk here is that the company may not raise its dividends as it did before. The key is to select the companies that can consistently raise its dividends. Usually companies with long history of raising dividends tend to do so.

Forest Laboratories 5-Year Yield-on-Cost % Related Terms

Thank you for viewing the detailed overview of Forest Laboratories's 5-Year Yield-on-Cost % provided by GuruFocus.com. Please click on the following links to see related term pages.

Forest Laboratories (FRA:FQX) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Forest Laboratories Inc (FRA:FQX) » Definitions » 5-Year Yield-on-Cost %

Comparable Companies

Traded in Other Exchanges

N/A

Address

Website

http://www.frx.com

Forest Laboratories, Inc. is a Delaware corporation organized in 1956. The Company develops, manufactures and sells branded forms of ethical drug products most of which require a physician's prescription. The Company's most important United States products are marketed directly, or 'detailed,' to physicians by its salesforces. It emphasizes detailing to physicians of those branded ethical drugs which have the most potential for growth and benefit to patients. The Company also develops and introduces new products, including products developed in collaboration with licensing partners. The Company's products include those developed by it and those acquired from other pharmaceutical companies and integrated into its marketing and distribution systems. It actively promotes in the United States those branded products which have the most potential for growth and patient benefit, and which enable its salesforces to concentrate on groups of physicians who are high prescribers of its products. Such products include: Lexapro, its SSRI for the treatment of major depression in adults and adolescents and GAD in adults; Namenda, its NMDA antagonist for the treatment of moderate and severe Alzheimer's disease; Bystolic, its beta-blocker for the treatment of hypertension; and Savella, its newest product, an SNRI for the management of fibromyalgia. The Company's United Kingdom and Ireland subsidiaries sell both ethical products and over-the-counter preparations. Their most important products include Sudocrem, a topical preparation for the treatment of diaper rash; Colomycin, an antibiotic used in the treatment of cystic fibrosis; Infacol, used to treat infant colic; and Exorex, used in the treatment of eczema and psoriasis. The pharmaceutical industry is subject to comprehensive government regulation which substantially increases the difficulty and cost incurred in obtaining the approval to market newly proposed drug products and maintaining the approval to market existing drugs.

Forest Laboratories (FRA:FQX) Headlines

No Headlines